Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

BTIG Keeps Their Buy Rating on Dexcom (DXCM)

Tipranks - Tipranks - Tue Apr 14, 6:50AM CDT

In a report released today, Marie Thibault from BTIG maintained a Buy rating on Dexcom, with a price target of $80.00.

Claim 30% Off TipRanks

According to TipRanks, Thibault is an analyst with an average return of -14.5% and a 31.59% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Boston Scientific, Kestra Medical Technologies Ltd., and Dexcom.

In a report released on April 7, Citi also reiterated a Buy rating on the stock with a $84.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Dexcom’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.26 billion and a net profit of $267.3 million. In comparison, last year the company earned a revenue of $1.11 billion and had a net profit of $151.7 million

Read More on DXCM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).